TICKERNERD
Menu
FLNAHealthcare · Biotechnology

FLNA Stock Forecast: Filana Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$1.03
+1.98% on the day

The 2 Wall Street analysts covering Filana Therapeutics, Inc. hold a median 12-month price target of $6.5 — +531.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 63 of 100 as at 1 Aug 2026 — in the upper half.

Market cap
$48.8M
Ticker Nerd rank
63 / 100
Median analyst target
$6.50
Analysts covering
2
Total return, dividends reinvested
1W
+14.4%
1M
−16.3%
YTD
−48.0%
1Y
−51.4%
From 52W high
−77.8%
From 52W low
+18.4%
$0.87
$4.64
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FLNA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Filana Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
63 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
86
Size
82
Accruals
76
Revisions
69
Issuance
62
Quality
47
Volatility
38
Value
19
Momentum
13

Growth (86): Sales and profits are climbing, and climbing faster than before.

Momentum (13): The shares have been drifting down relative to others.

The rank is the raw material. Whether the rules would actually own Filana Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

FLNA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FLNA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Oct 25Jan 26Apr 26Jul 26FLNAHigh $8.00Median $6.50Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $5.00Median $6.50High $8.00

The green dot is the last close — the median target sits +531.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
26 May 2026Maxim GroupReinstatesBuy$5.00
6 Oct 2025LUCID CAPITAL MARKETSInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

FLNA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Filana Therapeutics, Inc. (FLNA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.5×

Cheaper than 80% of US stocks

Price / sales
—
Price / book
0.8×

Cheaper than 79% of US stocks

EV / EBITDA
3.5×

Cheaper than 55% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−55.8%

Higher than 20% of US stocks

Return on assets
−5.6%

Higher than 31% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

FLNA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FLNAFilana Therapeutics, Inc.$48.8M
63
TCRXTScan Therapeutics, Inc.$48.6M
41
EDSAEdesa Biotech, Inc.$49.2M
59
TILInstil Bio, Inc.$48.3M
47
ATYRaTyr Pharma, Inc.$47.6M
35
BYSIBeyondSpring, Inc.$47.3M
19
INMBINmune Bio, Inc.$46.5M
43
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FLNA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest FLNA news & analysis

Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

GlobeNewsWire · 29 July 2026neutral

Filana Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2026, and provided a business update. The company currently focuses on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy.

Why it matters — This is a regular quarterly update that gives FLNA watchers a look at the company's financial performance and the status of its pipeline in TSC-related epilepsy.

FAQ

Frequently asked questions about FLNA stock

What is the FLNA stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Filana Therapeutics, Inc. have a median 12-month price target of $6.5, with estimates ranging from $5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FLNA stock a buy right now?

Of the 2 analysts covering Filana Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Filana Therapeutics, Inc. 63 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FLNA?

As at 1 Aug 2026, Filana Therapeutics, Inc. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).

Will FLNA stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +531.1% from the last close, and Ticker Nerd's factor model ranks Filana Therapeutics, Inc. 63 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FLNA stock forecast for 2030?

No analyst covering Filana Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FLNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $8 over the next 12 months.

How has FLNA stock performed over the past year?

Filana Therapeutics, Inc. returned -51.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Filana Therapeutics, Inc. do?

Filana Therapeutics is a biotechnology company focused on developing novel investigational therapies that modulate the filamin A protein for treating central nervous system disorders. The company's primary focus is on tuberous sclerosis complex (TSC)-related epilepsy and other conditions associated with filamin A dysregulation or overexpression.

What is the latest news on FLNA?

The most recent item we track (GlobeNewsWire, 29 July 2026): "Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update". Filana Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2026, and provided a business update. The company currently focuses on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy.

Company

About Filana Therapeutics, Inc.

Filana Therapeutics is a biotechnology company focused on developing novel investigational therapies that modulate the filamin A protein for treating central nervous system disorders. The company's primary focus is on tuberous sclerosis complex (TSC)-related epilepsy and other conditions associated with filamin A dysregulation or overexpression. Headquartered in Austin, Texas, and founded in 1998, Filana Therapeutics operates in the clinical development stage, working to advance its pipeline of filamin A-targeted candidates. The company is actively addressing FDA feedback related to its TSC program and is committed to bringing new treatment options to patients with limited therapeutic alternatives. Filana Therapeutics operates with a lean operational structure, emphasizing capital efficiency while pursuing its mission to develop meaningful medicines for neurological disorders tied to filamin A dysfunction.

CEO Mr. Richard Jon Barry · 17 employees · United States · https://www.filanatx.com